Skip to Content

N4P ” A little known story ”

Today I had a chat with Nigel Theabold CEO of N4 Pharma, the small private company hit the headlines when Aim listed investment company Onzima Ventures announced its investment for 49% of the company. The business works extensively on a number of compounds through the early development stage, with a novel structure which reduces significant dilution whilst focusing on progressing quickly into presenting its products through its technology platform.

  • Business model to reformulate and develop erectile dysfunction drugs
  • Strong background in product development working with Oxford Pharma Science
  • New clinical and commercial products into the forefront of industry
  • Regular focus on news flow with as the exciting outlook surfaces further

Related Articles


teathers app screenshot

App Empowering Private Investors

Crowd Equity for Placings, IPOs and Live Market Blockbuilds, designed to give provate investors access to placements and Intial Public Offerings (IPOs), predominantly on the London Stock Exchange’s Alternative Investment Market (AIM).